- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04231903
Myocardial Protection in Minimally Invasive Mitral Valve Surgery
Endo-aortic Versus Trans-thoracic Clamping in Right Mini-thoracotomy Mitral Valve Repair: Outcome on Myocardial Pro-tection
Perfusion strategies and aortic clamping techniques for right mini-thoracotomy mitral valve (MV) surgery have evolved over time and remarkable short- and long-term results have been re-ported. However, some concerns have emerged about the adequacy of myocardial protection dur-ing the minimally invasive approach and about the role of aortic clamping strategies in this contest.
Aim of this study was to compare the efficacy, in terms of myocardial protection, of the en-do-aortic clamp (EAC) versus the trans-thoracic aortic clamp (TTC) in patients undergoing right mini-thoracotomy MV repair.
A single center, prospective observational study was performed between June 2014 to June 2018 on patients undergoing right mini-thoracotomy MV repair with retrograde arterial perfusion and EAC or TTC. The selection of one setting in respect to the other was patient orientated. Myocardial protection was assessed through creatinine kinase-myocardial band (CK-MB) and cardiac Troponin T (cTn-T) blood levels immediately after the surgical procedure and at 6, 12, and 24 hours and compared between the two groups.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Surgical indication for mitral valve repair.
- Right mini-thoracotomy approach.
- Retrograde arterial perfusion.
Exclusion Criteria:
- Age more than 75 years.
- Cardiac ejection fraction lower than 40%.
- Previous cardiac surgery procedures for coronary artery bypass graft.
- Any degree of coronary artery disease.
- Severe peripheral vascular disease.
- Concomitant procedures for atrial fibrillation ablation.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
EAC
Patients undergoing surgery endo-aortic clamp.
|
In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
|
TTC
Patients undergoing surgery through trans-thoracic aortic clamp.
|
In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cTn-T levels immediately after surgery
Time Frame: Immediately after surgery
|
Myocardial protection was assessed through cardiac Troponin T (cTn-T) blood levels and compared between the 2 groups of aortic clamping
|
Immediately after surgery
|
CK-MB levels immediately after surgery
Time Frame: Immediately after the surgery
|
Myocardial protection was assessed through creatinine kinase-myocardial band (CK-MB) blood levels after right mini-thoracotomy mitral valve surgery and compared between the 2 groups of aortic clamping
|
Immediately after the surgery
|
cTn-T levels 6h
Time Frame: hour 6 after surgery
|
Myocardial protection was assessed through cardiac Troponin T (cTn-T) blood levels and compared between the 2 groups of aortic clamping
|
hour 6 after surgery
|
CK-MB levels 6h
Time Frame: hour 6 after surgery
|
Myocardial protection was assessed through creatinine kinase-myocardial band (CK-MB) blood levels after right mini-thoracotomy mitral valve surgery and compared between the 2 groups of aortic clamping
|
hour 6 after surgery
|
cTn-T levels 12h
Time Frame: hour 12 after surgery
|
Myocardial protection was assessed through cardiac Troponin T (cTn-T) blood levels and compared between the 2 groups of aortic clamping
|
hour 12 after surgery
|
CK-MB levels 12h
Time Frame: hour 12 after surgery
|
(CK-MB) blood levels after right mini-thoracotomy mitral valve surgery and compared between the 2 groups of aortic clamping
|
hour 12 after surgery
|
cTn-T levels 24h
Time Frame: hour 24 after surgery
|
Myocardial protection was assessed through cardiac Troponin T (cTn-T) blood levels and compared between the 2 groups of aortic clamping
|
hour 24 after surgery
|
CK-MB levels 24h
Time Frame: hour 24 after surgery
|
Myocardial protection was assessed through cardiac Troponin T (cTn-T) blood levels and compared between the 2 groups of aortic clamping
|
hour 24 after surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0063123
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Valve Prolapse
-
NeoChordRecruitingHeart Valve Diseases | Mitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Prolapse | Mitral Valve DiseaseGermany, Greece, Switzerland
-
Lawson Health Research InstituteUnknownMitral Regurgitation | Mitral Valve Prolapse | Mitral Valve Disease
-
Edwards LifesciencesTerminatedMitral Leaflet ProlapseItaly
-
Eric Y. Yang, MD PhDUnknownMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Prolapse | Ventricular Remodeling | Mitral Valve Disease | Degenerative Mitral Valve Disease | Chronic Mitral Disease | Myxomatous Mitral Valve DegenerationUnited States
-
Edwards LifesciencesCompletedMitral Valve Insufficiency | Mitral Valve Prolapse | Mitral Valve RegurgitationPoland
-
Edwards LifesciencesCompletedMitral Valve Insufficiency | Mitral Valve Prolapse | Mitral Valve RegurgitationPoland
-
Edwards LifesciencesCompletedMitral Valve Insufficiency | Mitral Valve Prolapse | Mitral Valve RegurgitationItaly, United Kingdom
-
Edwards LifesciencesTerminatedMitral Valve Insufficiency | Mitral Valve Prolapse | Mitral Valve RegurgitationPoland
-
National Heart Institute, EgyptUnknown
-
University of California, San FranciscoNot yet recruitingMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve ProlapseUnited States
Clinical Trials on Aortic clamp
-
Emory UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Collegium Medicum w BydgoszczyCompletedCoronary Artery Disease | Stroke | Postoperative Delirium | Postoperative Cognitive Dysfunction | Coronary Artery Bypass Surgery | Neurological Injury | Off-Pump Coronary Artery BypassPoland
-
Central South UniversityUnknownCardiopulmonary Bypass | Ischemic PostconditioningChina
-
University of Illinois College of Medicine at PeoriaOSF Healthcare SystemUnknown
-
Albert Einstein College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes | Malnutrition; Diabetes
-
TriHealth Inc.CompletedCircumcision, MaleUnited States
-
I.M. Sechenov First Moscow State Medical UniversityRecruitingRenal Cell CarcinomaRussian Federation
-
Brigham and Women's HospitalBeth Israel Deaconess Medical Center; Boston Children's Hospital; Mclean HospitalRecruitingHypoglycemia | Physiological StressUnited States
-
University of Ljubljana, Faculty of MedicineCompletedHyperglycemia | Type 1 Diabetes MellitusSlovenia